Track record

NMS scientists have also been involved in the making of company history through the discovery and development of numerous NCEs, listed below, subsequently marketed with success.

NCE	Trade-Mark	First Approval	Indication
Oncology
Daunorubicin	Daunoblastin ®	1968 (EU)	Hematological Tumours
Doxorubicin	Adriblastina ® Adriamycin ®	1971 (EU) 1986 (US)	Solid and Hematological Tumours
Epirubicin	Farmorubicin ® Ellence ®	1984 (EU) 1999 (US)	Solid and Hematological Tumours
Exemestane	Aromasin ®	1998 (EU) 1999 (US)	Breast Cancer
Idarubicin	Zavedos IV ® Idamycin® Zavedos Oral ®	1989 (EU) 1990 (US) 1990 (EU)	Acute leukemias
Other therapeutic areas
Cabergoline	Dostinex ®	1994 (EU) 1996 (US)	Hyperprolactinemia
	Cabaser ®	1996 (EU)	Parkinson's Disease
Glipizide	Glucotrol®/ Minidiab ®	1971 (EU)	Non-insulin-dependent diabetes
Reboxetine	Edronax ®	1997 (EU)	Antidepressant
Rifabutin	Mycobutin ®	1992 (EU) 1992 (US)	Anti-infective